Abstract 32P
Background
Secondary trastuzumab resistance seriously affects HER2-positive breast cancer treatment. However, we still lack knowledge about changes in tumor cells and their interaction with tumor microenvironment (TME) components during resistance formation. This study aimed to uncover metabolism pathway changes during trastuzumab resistance formation and potential epigenetic variations that are relevant to these processes.
Methods
Induced secondary trastuzumab-resistant SKBR3_HR cell line together with the original trastuzumab-sensitive SKBR3 cell line were applied in this study. Total RNA was collected for transcriptome analysis. Anti-H3K4me3, K27me3 and K27ac antibodies were chosen for CUT&Tag sequencing library preparation. Total genome DNA was prepared for Micro-C sequencing library preparation. Activity score of metabolism pathway was calculated as relative gene expression value averaged over all genes in this pathway in certain cell types. Extracellular prostaglandin E2 (PGE2) was measured by ELISA.
Results
SKBR3_HR cells showed higher trastuzumab tolerance than SKBR3 cells. Upregulation of arachidonic acid metabolism, which was characterized by two overexpressed genes, PTGS1 and PTGES, was observed in SKBR3_HR cells, resulting in PGE2 accumulation in culture medium. Variations of 1519 H3K27me3 peaks and 256 H3K4me3 peaks at promoters were observed during resistance formation. Little H3K27me3 but considerable raised H3K4me3 levels at PTGS1 and PTGES gene promoters may stimulate their transcription.692 altered active enhancers were measured during resistance formation. Meanwhile, 2741 and 7007 DNA loops were lost and gained. New DNA loops formation between PTGS1 gene promoter and enhancers nearby, indicating a positive synergy regulatory on PTGS1 gene expression together with promoter modifications.
Conclusions
During trastuzumab resistance formation, promoter H3K4me3, active enhancers and DNA loops together regulate PTGS1 and PTGES expression, activate arachidonic acid metabolism, and eventually stimulate PGE2 accumulation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Natural Science Foundation of China (81972484), National Natural Science Foundation of China (82203488).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
78P - Peroxiredoxin-1 knockout negatively affects the viability of ph+ B-cell acute lymphoblastic leukemia cells and sensitizes them to tyrosine kinase inhibitors
Presenter: Jaromir Hunia
Session: Poster session 09
79P - Co-delivered crizotinib and gefitinib based on nanoparticle for synergically overcoming resistance lung adenocarcinoma treatment
Presenter: Haiyu Zhou
Session: Poster session 09
80P - Steroidal oximes: A new potential therapeutic approach for cancer treatment
Presenter: Mafalda Laranjo
Session: Poster session 09
81P - miR-23b and -133a role on TRAIL-induced apoptosis pathway components expression and TRAIL sensitization in lung adenocarcinoma cells
Presenter: Denise Leite
Session: Poster session 09
83P - Impact of VHL-associated tumor treatment on mental health: An international patient survey
Presenter: Othon Iliopoulos
Session: Poster session 09
84P - Microenvironment immune differences between sexes in multiple myeloma
Presenter: Maria de los Angeles Clavo
Session: Poster session 09
85P - In silico evaluation of the transcriptomic and immunologic profile of lung adenocarcinomas with deletions or disruptive mutations of SMARCA4
Presenter: Ester Garcia Lorenzo
Session: Poster session 09
86P - Effect of chemotherapy-induced autophagic secretome on natural killer cell activity
Presenter: Ayfer Karlitepe
Session: Poster session 09
87P - WIP1 phosphatase promotes etoposide induced autophagy in medulloblastoma and neuroblastoma
Presenter: Hatice Pilevneli
Session: Poster session 09
88P - PPM1D/WIP1 phosphatase mediates basal and genotoxic stress-induced autophagy via ULK-1 de-phosphorylation
Presenter: Ceylan Ak
Session: Poster session 09